Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Essentials Marzeptacog alfa (activated) [MarzAA] is a novel variant of activated human factor VII. A phase 1 dose escalation trial of MarzAA was conducted in subjects with severe hemophilia. MarzAA was safe and tolerated at intravenous doses up to 30 μg kg-1 Data observed support further trials for hemophilia patients with inhibitors to factors VIII/IX.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J. Thromb. Haemost.

Title: Journal of thrombosis and haemostasis : JTH

Publisher: Wiley

ISSN (Electronic): 1538-7836

ISSN (Print): 1538-7836

Publication date (Electronic): Oct 2018

Volume: 16

Issue: 10

Affiliations

[1 ] Comprehensive Hemophilia and Thrombosis Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

[2 ] Phoenix Pharma Pty Ltd, Mount Croix, Port Elizabeth, South Africa.

[3 ] Semmelweis University 1st Department of Medicine, Budapest, Hungary.

[4 ] National Hemophilia Center and Hemostasis Department, Medical Center of the Hungarian Defense Forces, Budapest, Hungary.

[5 ] University Department of Haematology, Manchester Royal Infirmary, Manchester, UK.

[6 ] Hemophilia and Thrombophilia Center, Rush University Medical Center, Chicago, IL, USA.

[7 ] KD Haemophilia and Thrombosis Centre, Royal Free Hospital, London, UK.

[8 ] Department of Medicine, Hemophilia Center, Castelfranco Veneto Hospital, Castelfranco, Italy.

[9 ] University of California San Diego, San Diego, CA, USA.

[10 ] Applied BioMath, Concord, MA, USA.

[11 ] Early Clinical Development, Pfizer Worldwide R&D, Pfizer Inc., Cambridge, MA, USA.

[12 ] Rare Disease Research Unit, Pfizer Inc., Cambridge, MA, USA.

Article

DOI: 10.1111/jth.14247

PubMed ID: 30151972

SO-VID: e67fc039-2e3b-4765-b159-36a0785d84ae

History

Keywords: hemophilia A,hemophilia B,factor VIIa,blood coagulation,clinical trial

Data availability:

Keywords: hemophilia A, hemophilia B, factor VIIa, blood coagulation, clinical trial

Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia.

Read this article at

Abstract

Related collections

Drug Repurposing

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 681

Cited by 8